Crohn's Disease

J&J Announces STELARA® FDA Approval for Pediatric Crohn’s Disease

By Regulatory Intelligence Desk
2 May 2026

The recent STELARA FDA approval provides a crucial new non-TNF biologic treatment option for children two years and older suffering from moderately to severely active Crohn’s disease.

Clinical Trials Autoimmune Diseases News

Lilly’s Omvoh Shows Sustained, Long-Term Efficacy in Ulcerative Colitis and Crohn’s Disease

By Athulya B S
8 October 2025

Eli Lilly and Company announced a significant milestone for Omvoh (mirikizumab-mrkz), which is now the first and only IL-23p19 antagonist to demonstrate four years of sustained, corticosteroid-free comprehensive patient outcomes for individuals living with ulcerative colitis (UC).

Tag: Crohn’s Disease

J&J Announces STELARA® FDA Approval for Pediatric Crohn’s Disease

Lilly’s Omvoh Shows Sustained, Long-Term Efficacy in Ulcerative Colitis and Crohn’s Disease

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement